At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Jan Soupal discusses the latest data from the COMISAIR study.
1. Could you tell us a little about the aims and design of the COMISAIR trial? (0:05)
2. What were the major findings of this study? (2:22)
3. What were the limitations of this study and what future studies are planned? (2:58)
4. How have these findings changed the role of continuous glucose monitoring (CGM) and insulin delivery in the management of type 1 diabetes? (3:44)
5. What barriers exist to the wider utilisation of CGM and how may they be overcome? (4:16)
Jan Soupal has no conflicts of interest to declare in relation to this video.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021 – Anticipated congress highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20-1:30) What have we learned about the […]
Welcome to the IDF Virtual Congress 2021
Programme Chair Prof. João Filipe Raposo introduces the programme for the International Diabetes Federation (IDF) Virtual Congress 2021 (December 6-11) focusing on diabetes complications and the links between COVID-19 and diabetes. https://www.idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!